Novel targeted agents for the treatment of lung cancer in China-Reference-Cited by-同舟云学术

Novel targeted agents for the treatment of lung cancer in China

Published:2015-09-01 Issue:S17 Volume:121 Page:3089-3096
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Liu Si-Yang¹,Mok Tony²,Wu Yi-Long¹

Affiliation:

1. Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Guangzhou China

2. State Key Laboratory of Southern China; The Chinese University of Hong Kong, Sir Y.K. Pau Cancer Center, Prince of Wales Hospital; Hong Kong China

Funder

Special Fund for Research in the Public Interest from National Health and Family Planning Commission of PRC

The Key Technologies R & D Program of Guangzhou

Key Laboratory Program of Guangdong

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29522/fullpdf

Reference58 articles.

1. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med,2009

2. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi;Lancet Oncol,2010

3. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR;Maemondo;N Engl J Med,2010

4. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

5. Spanish Lung Cancer Group in collaboration with Groupe Francais de Pneumo-Cancerologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SMARCA4‑deficient non‑small cell lung cancer with an EGFR mutation: A case report;Oncology Letters;2023-10-13

2. Perioperative targeted therapy for oncogene-driven NSCLC;Lung Cancer;2022-10

3. Recent advancements in coralyne (COR)-based biosensors: Basic principles, various strategies and future perspectives;Biosensors and Bioelectronics;2022-08

4. Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China;Frontiers in Oncology;2021-04-13

5. Elevation of EIF4G1 promotes non‐small cell lung cancer progression by activating mTOR signalling;Journal of Cellular and Molecular Medicine;2021-02